248 related articles for article (PubMed ID: 25597708)
21. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
Youn Y; Kim J; Hong YM; Sohn S
Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
[TBL] [Abstract][Full Text] [Related]
22. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
Son MB; Gauvreau K; Burns JC; Corinaldesi E; Tremoulet AH; Watson VE; Baker A; Fulton DR; Sundel RP; Newburger JW
J Pediatr; 2011 Apr; 158(4):644-649.e1. PubMed ID: 21129756
[TBL] [Abstract][Full Text] [Related]
23. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
Michihata N; Matsui H; Fushimi K; Yasunaga H
Clin Pediatr (Phila); 2015 Oct; 54(11):1076-80. PubMed ID: 25573948
[TBL] [Abstract][Full Text] [Related]
24. Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High-Risk Patients With Kawasaki Disease.
Ae R; Abrams JY; Maddox RA; Schonberger LB; Nakamura Y; Kuwabara M; Makino N; Matsubara Y; Kosami K; Sasahara T; Belay ED
J Am Heart Assoc; 2020 Sep; 9(17):e015308. PubMed ID: 32811256
[TBL] [Abstract][Full Text] [Related]
25. Kawasaki disease in Jordan: demographics, presentation, and outcome.
Al-Ammouri I; Al-Wahsh S; Khuri-Bulos N
Cardiol Young; 2012 Aug; 22(4):390-5. PubMed ID: 22067065
[TBL] [Abstract][Full Text] [Related]
26. Kawasaki disease: an essential comparison of coronary artery aneurysm criteria.
Burns JC; Hoshino S; Kobayashi T
Lancet Child Adolesc Health; 2018 Dec; 2(12):840-841. PubMed ID: 30337184
[No Abstract] [Full Text] [Related]
27. Evaluation of clinical characteristics of Kawasaki syndrome and risk factors for coronary artery abnormalities among children in Denmark.
Patel A; Holman RC; Callinan LS; Sreenivasan N; Schonberger LB; Fischer TK; Belay ED
Acta Paediatr; 2013 Apr; 102(4):385-90. PubMed ID: 23278838
[TBL] [Abstract][Full Text] [Related]
28. Quantitative evaluation of coronary artery wall echogenicity by integrated backscatter analysis in Kawasaki disease.
Abe O; Karasawa K; Hirano M; Miyashita M; Taniguchi K; Ayusawa M; Sumitomo N; Okada T; Harada K; Mugishima H
J Am Soc Echocardiogr; 2010 Sep; 23(9):938-42. PubMed ID: 20656453
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ; Wang HW; Hu XF; Liu QJ; Shi H; Wei YX; Chen QJ; Cheng PX
Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):891-5. PubMed ID: 17254453
[TBL] [Abstract][Full Text] [Related]
30. [Association of new functional SNP rs72689236 of CASP3 with Kawasaki disease: a meta-analysis].
Peng Q; Chen CH; Wu Q; Yang Y
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):477-83. PubMed ID: 23791066
[TBL] [Abstract][Full Text] [Related]
31. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis].
Servel AC; Vincenti M; Darras JP; Lalande M; Rodière M; Filleron A
Arch Pediatr; 2012 Jul; 19(7):741-4. PubMed ID: 22652521
[TBL] [Abstract][Full Text] [Related]
32. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of Kawasaki disease by different doses of immunoglobulin: a Mata analysis of therapeutic effects].
Chen J; Ma B; Lin LX; Xue YM
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Aug; 13(8):638-43. PubMed ID: 21849113
[TBL] [Abstract][Full Text] [Related]
34. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
Durongpisitkul K; Gururaj VJ; Park JM; Martin CF
Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
[TBL] [Abstract][Full Text] [Related]
35. Stratified therapy for Kawasaki disease using a new scoring system to predict the response to a lower dose of intravenous immunoglobulin therapy.
Matsuura M; Sugawara D; Makita E; Hirakubo Y; Nonaka K; Yamashita S; Ichihashi K
Cardiol Young; 2022 Mar; 32(3):405-409. PubMed ID: 34108062
[TBL] [Abstract][Full Text] [Related]
36. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
Dale RC; Saleem MA; Daw S; Dillon MJ
J Pediatr; 2000 Nov; 137(5):723-6. PubMed ID: 11060542
[TBL] [Abstract][Full Text] [Related]
37. Response of refractory Kawasaki disease to intravenous methylprednisolone.
Shah I; Prabhu SS
Ann Trop Paediatr; 2009 Mar; 29(1):51-3. PubMed ID: 19222935
[TBL] [Abstract][Full Text] [Related]
38. Transient Deformation of Neutrophils in Kawasaki Disease.
Koike Y; Yanagisawa R; Ogiso Y; Cho Y; Minami K; Takeuchi K; Sakashita K; Higuchi T
J Pediatr; 2016 Jun; 173():238-241.e1. PubMed ID: 27039225
[TBL] [Abstract][Full Text] [Related]
39. [Kawasaki disease in children--9 years experience].
Kowalczyk M; Kawalec W; Daszkowska-York J; Turska-Kmieć A; Brzezińska-Rajszys G; Sobielarska D; Ziółkowska L; Kościesza A; Jagiełłowicz D; Mirecka-Rola A
Med Wieku Rozwoj; 2005; 9(2):179-93. PubMed ID: 16085959
[TBL] [Abstract][Full Text] [Related]
40. Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin--an effective and cost-saving schedule of therapy.
Ichihashi K; Shiraishi H; Momoi M
Cardiol Young; 2009 Jun; 19(3):224-7. PubMed ID: 19272202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
